Lexicon Pharmaceuticals (NASDAQ:LXRX) Posts Earnings Results, Misses Estimates By $0.13 EPS

Lexicon Pharmaceuticals (NASDAQ:LXRX) issued its earnings results on Wednesday. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.13), Briefing.com reports. The firm had revenue of $9.68 million during the quarter, compared to the consensus estimate of $28.52 million. Lexicon Pharmaceuticals’s revenue for the quarter was down 29.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.33) EPS.

NASDAQ:LXRX traded down $0.11 during mid-day trading on Friday, reaching $1.20. The stock had a trading volume of 3,300,815 shares, compared to its average volume of 2,008,231. The company has a 50 day moving average of $5.46. Lexicon Pharmaceuticals has a fifty-two week low of $1.13 and a fifty-two week high of $11.88.

In other news, Director Sam L. Barker acquired 24,000 shares of the company’s stock in a transaction that occurred on Friday, August 2nd. The shares were purchased at an average price of $1.18 per share, for a total transaction of $28,320.00. Following the completion of the acquisition, the director now owns 40,187 shares of the company’s stock, valued at approximately $47,420.66. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 6.40% of the company’s stock.

A number of equities analysts have recently weighed in on the company. ValuEngine upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. Wedbush reiterated an “outperform” rating and issued a $17.00 target price (down previously from $35.00) on shares of Lexicon Pharmaceuticals in a report on Thursday. BidaskClub downgraded Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 19th. Citigroup dropped their price objective on Lexicon Pharmaceuticals from $15.00 to $3.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Stifel Nicolaus downgraded Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $10.00 to $4.00 in a report on Monday, July 29th. One research analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $7.63.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Article: Moving Average (MA)

Earnings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.